Open AccessThis article is
- freely available
Role of Met Axis in Head and Neck Cancer
Department of Dermatology, University of Michigan, Ann Arbor, MI 48109, USA
* Authors to whom correspondence should be addressed.
Received: 15 October 2013; in revised form: 12 November 2013 / Accepted: 14 November 2013 / Published: 26 November 2013
Abstract: Head and neck cancer is the sixth most common type of cancer worldwide. Despite advances in aggressive multidisciplinary treatments, the 5-year survival rate for this dreadful disease is only 50%, mostly due to high rate of recurrence and early involvement of regional lymph nodes and subsequent metastasis. Understanding the molecular mechanisms responsible for invasion and metastasis is one of the most pressing goals in the field of head and neck cancer. Met, also known as hepatocyte growth factor receptor (HGFR), is a member of the receptor protein tyrosine kinase (RPTK) family. There is compelling evidence that Met axis is dysregulated and plays important roles in tumorigenesis, progression, metastasis, angiogenesis, and drug resistance in head and neck cancer. We describe in this review current understanding of Met axis in head and neck cancer biology and development of therapeutic inhibitors targeting Met axis.
Keywords: head and neck cancer; receptor protein tyrosine kinase; hepatocyte growth factor receptor
Citations to this Article
Cite This Article
MDPI and ACS Style
Xu, Y.; Fisher, G.J. Role of Met Axis in Head and Neck Cancer. Cancers 2013, 5, 1601-1618.
Xu Y, Fisher GJ. Role of Met Axis in Head and Neck Cancer. Cancers. 2013; 5(4):1601-1618.
Xu, Yiru; Fisher, Gary J. 2013. "Role of Met Axis in Head and Neck Cancer." Cancers 5, no. 4: 1601-1618.